Biopharma Daily Stock Updates - 02/01/21

$XBI $159.62 +4.41% 📈


COVID:

$AMPE +15% - AMPIO ANNOUNCES EARLY POSITIVE DATA IN PHASE 1 TRIAL OF INHALED AMPION IN COVID-19 RESPIRATORY DISTRESS


$DVAX +62% - Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response


$DVAX +62% - Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate


$IMNM +18% - Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus


$SRNE +15% - Update to 01/26/21 COVI-MSCâ„¢ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells


PIPELINE:

$ADMS +15% - Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes


$MIRM +5% - Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome


$KDMN +5% - Kadmon Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor Response


$SESN +2% - Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineumâ„¢


$ADMA +10% - ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN


$ARQT +30% - Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis


$RMI +1% - Rockwell Medical Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.


$CNCE -28% - CONCERT PHARMACEUTICALS ANNOUNCES RESULTS FROM CTP-692 PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA


$GRTS -5% - Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure


$ZGNX +2% - Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome


FINANCIAL:

$VIE +52% - Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio


$ARQT +30% - Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock


$ADMS +15% - Adamas Announces Settlement of Patent Litigation with Zydus


$MNOV + 1% - Issued $20 million private placement


$MNOV +1% - MediciNova Announces Closing of US$20 Million Private Placement Transaction

0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Moversâ„¢ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE